A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report
Abstract Background The identification of NTRK fusions in tumours has become critically important due to the actionable events predictive of response to TRK inhibitor. It is not clear whether the NTRK breakpoint location is different for response to targeted therapy and NTRK fusions affects the effi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-04-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12890-021-01490-x |
| _version_ | 1818414535459995648 |
|---|---|
| author | Lei Zhang Huanhuan Liu Ye Tian Huina Wang Xueying Yang |
| author_facet | Lei Zhang Huanhuan Liu Ye Tian Huina Wang Xueying Yang |
| author_sort | Lei Zhang |
| collection | DOAJ |
| description | Abstract Background The identification of NTRK fusions in tumours has become critically important due to the actionable events predictive of response to TRK inhibitor. It is not clear whether the NTRK breakpoint location is different for response to targeted therapy and NTRK fusions affects the efficacy of immunotherapy. Case presentation Here we reported a 60-year-old female diagnosed with advanced lung adenocarcinoma. NGS-based molecular profiling identified a novel NCOR2-NTRK1 fusion and high tumor mutational burden (TMB) (58.58 mutations/Mb) in this case. Additionally, program death-ligand 1 (PD-L1) expression was detected in 20–30% of the tumor cells by immunohistochemical (IHC) staining. The patient received treatment with anti-PD-1 immune checkpoint inhibitor of camrelizumab. After two cycles of treatment, the CT scan showed some tumor nodules were still enlarged, indicating disease progression. She was then changed to TRK inhibitor larotrectinib. One month later, the CT scan showed the volume of some lesions started to decrease, and no metastasis lesions were found. The patient then continued the administration of larotrectinib, and some lesion sizes were significantly reduced or even disappeared in the next few months. Currently, this patient is still alive. Conclusions Altogether, this report provided a new driver of lung adenocarcinoma expanded the mutational spectrum of NTRK1 fusion variants and suggested using larotrectinib as the targeted therapy is more effective than anti-PD-1 inhibitor in lung adenocarcinoma harboring with NTRK fusion, positive PD-L1 expression, and high TMB simultaneously. |
| first_indexed | 2024-12-14T11:20:39Z |
| format | Article |
| id | doaj.art-0e06223fb7e7491a99caeed19ac25123 |
| institution | Directory Open Access Journal |
| issn | 1471-2466 |
| language | English |
| last_indexed | 2024-12-14T11:20:39Z |
| publishDate | 2021-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pulmonary Medicine |
| spelling | doaj.art-0e06223fb7e7491a99caeed19ac251232022-12-21T23:03:46ZengBMCBMC Pulmonary Medicine1471-24662021-04-012111510.1186/s12890-021-01490-xA novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case reportLei Zhang0Huanhuan Liu1Ye Tian2Huina Wang3Xueying Yang4Department of Thoracic Surgery, The Fourth Affiliated Hospital of China Medical UniversityAcornmed Biotechnology Co., Ltd.Department of Thoracic Surgery, The Fourth Affiliated Hospital of China Medical UniversityAcornmed Biotechnology Co., Ltd.Department of Thoracic Surgery, The Fourth Affiliated Hospital of China Medical UniversityAbstract Background The identification of NTRK fusions in tumours has become critically important due to the actionable events predictive of response to TRK inhibitor. It is not clear whether the NTRK breakpoint location is different for response to targeted therapy and NTRK fusions affects the efficacy of immunotherapy. Case presentation Here we reported a 60-year-old female diagnosed with advanced lung adenocarcinoma. NGS-based molecular profiling identified a novel NCOR2-NTRK1 fusion and high tumor mutational burden (TMB) (58.58 mutations/Mb) in this case. Additionally, program death-ligand 1 (PD-L1) expression was detected in 20–30% of the tumor cells by immunohistochemical (IHC) staining. The patient received treatment with anti-PD-1 immune checkpoint inhibitor of camrelizumab. After two cycles of treatment, the CT scan showed some tumor nodules were still enlarged, indicating disease progression. She was then changed to TRK inhibitor larotrectinib. One month later, the CT scan showed the volume of some lesions started to decrease, and no metastasis lesions were found. The patient then continued the administration of larotrectinib, and some lesion sizes were significantly reduced or even disappeared in the next few months. Currently, this patient is still alive. Conclusions Altogether, this report provided a new driver of lung adenocarcinoma expanded the mutational spectrum of NTRK1 fusion variants and suggested using larotrectinib as the targeted therapy is more effective than anti-PD-1 inhibitor in lung adenocarcinoma harboring with NTRK fusion, positive PD-L1 expression, and high TMB simultaneously.https://doi.org/10.1186/s12890-021-01490-xLung adenocarcinomaNTRK fusionPD-L1LarotrectinibCase report |
| spellingShingle | Lei Zhang Huanhuan Liu Ye Tian Huina Wang Xueying Yang A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report BMC Pulmonary Medicine Lung adenocarcinoma NTRK fusion PD-L1 Larotrectinib Case report |
| title | A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report |
| title_full | A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report |
| title_fullStr | A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report |
| title_full_unstemmed | A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report |
| title_short | A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report |
| title_sort | novel ncor2 ntrk1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib a case report |
| topic | Lung adenocarcinoma NTRK fusion PD-L1 Larotrectinib Case report |
| url | https://doi.org/10.1186/s12890-021-01490-x |
| work_keys_str_mv | AT leizhang anovelncor2ntrk1fusiondetectedinapatientoflungadenocarcinomaandresponsetolarotrectinibacasereport AT huanhuanliu anovelncor2ntrk1fusiondetectedinapatientoflungadenocarcinomaandresponsetolarotrectinibacasereport AT yetian anovelncor2ntrk1fusiondetectedinapatientoflungadenocarcinomaandresponsetolarotrectinibacasereport AT huinawang anovelncor2ntrk1fusiondetectedinapatientoflungadenocarcinomaandresponsetolarotrectinibacasereport AT xueyingyang anovelncor2ntrk1fusiondetectedinapatientoflungadenocarcinomaandresponsetolarotrectinibacasereport AT leizhang novelncor2ntrk1fusiondetectedinapatientoflungadenocarcinomaandresponsetolarotrectinibacasereport AT huanhuanliu novelncor2ntrk1fusiondetectedinapatientoflungadenocarcinomaandresponsetolarotrectinibacasereport AT yetian novelncor2ntrk1fusiondetectedinapatientoflungadenocarcinomaandresponsetolarotrectinibacasereport AT huinawang novelncor2ntrk1fusiondetectedinapatientoflungadenocarcinomaandresponsetolarotrectinibacasereport AT xueyingyang novelncor2ntrk1fusiondetectedinapatientoflungadenocarcinomaandresponsetolarotrectinibacasereport |